PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
about
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsPI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutationsComparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.The AURORA initiative for metastatic breast cancer.MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancersTargeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.Multiple gene aberrations and breast cancer: lessons from super-responders.DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerUpregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathwayInfiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profileGenomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.Heterogeneity of breast cancer: etiology and clinical relevance.Lobular breast cancer: pathology, biology, and options for clinical intervention.Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.Clinical management of breast cancer heterogeneity.PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.Oncogenic PIK3CA mutations in lobular breast cancer progression.PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.Tumor Heterogeneity in Breast Cancer.Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231).Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
P2860
Q26749011-92EB4DAE-1DE9-4991-B068-0D586D1C7D32Q33587930-E4863573-0ABB-4634-981C-683EA8E8AC1BQ33608197-1BC95414-14B6-4635-BAE7-E680B2946E25Q33674656-BD1DC6ED-72DA-4824-A3DA-CF0334FD495AQ34033475-9CBEC029-24B1-4C7F-9DC4-017B7711246CQ34499602-DC6D9FB5-BF87-40B2-9424-EEDA3F398BC8Q34991267-4E003491-4E47-41D1-902C-A3DB487BFADDQ35092806-7F73EB08-8EA0-4123-8FDC-3A1E19BBA27EQ35645466-DD5CFD10-906A-4ADA-B57B-45B6309BB6F2Q35740115-6EF6EDA8-5774-424D-AC4F-7275F81DD4EAQ35861503-43AF9979-5266-4D81-AB2E-831FA74FA8F8Q36244592-6394A20D-1E23-40DC-8D5E-A5F47D374C07Q36476312-57E38CBA-F584-4734-A1C1-1025D61BDCA5Q37046419-6F637D57-E599-445E-9174-AC3E7F56ECCEQ37119308-F85D9CD1-4214-4479-82D1-6859EE0E4376Q37155717-E84F6B11-CDE5-47A1-AFCE-42BE02D4EC90Q37956043-3ABB7DC8-82DF-4BDE-8D7A-FAFD0E6557E4Q38130105-52A55ADA-BAB4-4557-BB9B-2B4F2E9800FCQ38376017-BDADF5D1-8A9D-4869-B6EC-C91F6D6C94A8Q38431284-8DC91B2E-36C6-4541-A89C-A4F24A61AA18Q39050475-2333C6D2-5AC1-43BE-B3A7-62A46C94B6BBQ42324115-415D3CAB-806E-4C13-8884-CC8BE18E18CFQ42513022-06C379D9-F646-46BB-8032-2CEEFC7086A9Q44585456-4F9BC2FC-C9A8-49CA-9034-ED989DBA6304Q47146956-958F0EE4-BAF4-448F-B8D5-C080C1F5C1ECQ48152048-20EA62B2-3D4C-449C-BEC5-3D9124A6FDBAQ49179749-4E66A36C-7701-41CF-9B90-D8C40EDC8BE0Q53272132-32113532-4DC6-4FAE-BDE6-2479E33526C1Q54396852-ADC04A32-A1EB-41BB-A55A-5C64EF571E16Q54399355-E747D57D-E26D-43B2-9911-292603B031F2
P2860
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
PIK3CA mutations rarely demons ...... in breast cancer progression.
@en
PIK3CA mutations rarely demons ...... in breast cancer progression.
@nl
type
label
PIK3CA mutations rarely demons ...... in breast cancer progression.
@en
PIK3CA mutations rarely demons ...... in breast cancer progression.
@nl
prefLabel
PIK3CA mutations rarely demons ...... in breast cancer progression.
@en
PIK3CA mutations rarely demons ...... in breast cancer progression.
@nl
P2093
P2860
P1476
PIK3CA mutations rarely demons ...... r in breast cancer progression
@en
P2093
Adriana Heguy
Kevin Kalinsky
Sujata Patil
P2860
P2888
P304
P356
10.1007/S10549-011-1601-4
P407
P577
2011-05-27T00:00:00Z